Investigating cell, tissue and gene therapy products and their regulation

Biosimilars/Research | Posted 12/12/2022 post-comment0 Post your comment

Cell, tissue and gene therapy products or (CTGTPs) are often breakthrough therapies with immense potential in treating diseases with no cure or rare diseases with high treatment burdens. However, few of such therapies have been approved and some have been recalled due to safety issues. Now, a study published in GaBI Journal [1] has investigated these therapies and the manufacturing and regulatory challenges they pose.

Autologous Stem Cells V13F14

The review highlights that CTGTPs are intended for use in humans for curative, prophylactic, palliative or diagnostic purposes and target diseases that are managed by therapies with high treatment burdens. CTGTPs include the use of stem cells for regenerative purposes, the insertion of genes related to the production of specific proteins in gene therapies for cancer and rare disease treatment, and the engineering of components involving cells and tissue architectures to mend and restore organs and tissues in tissue therapy. CTGTPs are also known as advanced therapy medicinal products or regenerative medicines.

CTGTPs are not conventional biologicals and are derived directly from individual patients or donors. To be produced, e.g. cells, tissues are required, whereas for conventional biological medicines the focus is on producing specific protein products. As such, storage, transport and cryopreservation of CTGTPs in the manufacturing cycle are key as cells require extreme cryopreservation temperatures, and heterogeneity has to be managed if the therapy product is autologous (from the patient). As a result, when compared to general biologicals, far more stringent processes are required in the manufacturing of CTGTPs. It is noted that some solutions to the challenges encountered in manufacturing include ensuring appropriate accreditation of professionals handling CTGTPs, using automation and outsourcing to contract development and manufacturing organizations to ensure better compliance to good manufacturing practice (GMP) standards.

The review elaborates that a great need for development of specific regulations and regulatory frameworks related to CTGTPs. It outlines that challenges faced in the manufacturing and regulation of CTGTPs include quality assurance issues, lack of expertise and limitations in technology. Overall, a global convergence in regulation related to CTGTPs is needed through global harmonization of information related to these innovative therapies. However, as they continue to evolve, regulation needs to be dynamic and responsive to advances. It is suggested that, to ensure these therapies are accessible to patients and have global reach, there needs to be greater and more effective communication between regulators and different stakeholders such as manufacturers, with feedback and some degree of flexibility incorporated into regulations.

GaBI Journal Citation Impact
2.2 – CiteScore 2021 (calculated on 5 May 2022)
2.4 – CiteScoreTracker 2022 (Last updated on 6 December 2022)

Submit a manuscript to GaBI Journal

Related articles
Technological approaches to drug repurposing for cancer treatment

Biopharmaceuticals and biosimilars: manufacturing processes

FDA approves drug for cancers with specific biomarker

LATIN AMERICAN FORUM
The new section of the ‘Latin American Forum’ on GaBI has been launched. The objective of this new section is to provide you with all the latest news and updates on developments of generic and biosimilar medicines in Latin America in Spanish.

View the latest headline article: Directrices para la regulación de biológicos, biosimilares y radiofármacos en Brasil

Browse the news in the Latin American Forum!

Register to receive the GaBI Latin American Forum newsletter. Inform colleagues and friends of this new initiative.

FORO LATINOAMERICANO
Se ha lanzado la nueva sección del ‘Foro Latinoamericano’ sobre GaBI. El objetivo de esta nueva sección es brindarle las últimas noticias y actualizaciones sobre desarrollos de medicamentos genéricos y biosimilares en América Latina en español.

Ver el último artículo de cabecera: Directrices para la regulación de biológicos, biosimilares y radiofármacos en Brasil

!Explore las noticias en el Foro Latinoamericano!

Regístrese para recibir el boletín informativo GaBI Foro Latinoamericano. Informe a colegas y amigos sobre esta nueva iniciativa. 

 

Reference
1. Sia CH, Koh C, Chan LW. Manufacture and regulation of cell, tissue and gene therapy products: global perspectives, challenges and next steps. Generics and Biosimilars Initiative Journal (GaBI Journal). 2022;11(2):65-81. doi:10.5639/gabij.2022.1102.012

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2022 Pro Pharma Communications International. All Rights Reserved.

comment icon Comments (0)
Post your comment
Related content
Investigating biosimilar product drift and divergence
T cell V21G23
Biosimilars/Research Posted 25/11/2022
The cost savings of non-medical switching in dermatology
MD002152
Biosimilars/Research Posted 04/11/2022
Most viewed articles
About GaBI
Home/About GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010